Texas Instruments Incorporated (NASDAQ:TXN) shares were trading higher by 0.57 percent ($0.56) at $98.54 a piece in Monday’s session. It had closed the previous session at $97.98. TXN trades with a P/S ratio of 6.66. This is lower than the industry’s 16.95 but higher compared with the wider sector’s 2.91. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 21.66 and a trailing 12-month price-earnings (P/E) multiple of 22.44. Shares of TXN have uptrended 19.51% in the past three months, while the S&P 500 has moved 15.16% in that time. Texas Instruments Incorporated (TXN) has a market cap of $97.36 billion and over the last 12 months, Texas Instruments Incorporated (NASDAQ:TXN) has gone stronger by 45.77%. During the last 52 weeks, the (NASDAQ:TXN) price has been as high as $98 and as low as $66.8. Texas Instruments Incorporated earnings have risen with an annualized rate of 13.1% over the last 5 years. The average 1-year price target for Texas Instruments Incorporated (TXN) — averaging the work of different analysts — reveals a mean PT of $100.43/share. That’s a potential 1.92 increase relative to where Texas Instruments Incorporated (NASDAQ:TXN) has been trading recently. The current price is seen ranging between $97.67 and $98.67. There are brokerage firms with lower targets than the average, including one setting a price target of $85. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $120. The collective rating of 2.4 for Texas Instruments Incorporated (NASDAQ:TXN) also leans strongly towards the neutral end of the spectrum. Of the 32 analysts surveyed by Reuters that track TXN 17 of them rate its stock a hold. The other 15, though not evenly; between analysts who think you should buy Texas Instruments Incorporated versus those who think you should sell it. A 14 analysts rate it as either a buy or a strong buy, while1 believe that investors should either steer clear of TXN or, if they already own its stock, sell it. HCA Healthcare, Inc. (HCA) pulled off a 0.58 percent gain and now trades for $76.87. HCA comes in with a P/S ratio of 0.66 that’s below 1, potentially implying that it could be cheap relative to the overall sector (5.19) and its peers (13.82). Also, it has an estimated price-earnings (P/E) multiple of 10.47 and a trailing 12-month price-earnings (P/E) multiple of 10.3. During the last 52 weeks, the price has been as high as $91.03 and as low as $67. HCA Healthcare, Inc. (NYSE:HCA) earnings have risen with a quarterly rate of 6.9% over the last 5 years. Shares of HCA have sank -1.61% in the past three monthswhile the S&P 500 has dropped -15.36% in that time. HCA Healthcare, Inc. (NYSE:HCA) has a market cap of $27.77 billion and over the last 12 months, HCA has risen by 2.04%. The average 1-year price target for (HCA) reveals an average price target of $86.65 per share. That’s a potential 12.72 gain from where (NYSE:HCA) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $75. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $95. The consensus recommendation — averaging the work of 21 analysts — of 2 for HCA Healthcare, Inc. (HCA) points to moderate case. Of the analysts surveyed by Reuters that track HCA Healthcare, Inc. 6 of them rate its stock a hold. The other 15 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 15 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NYSE:HCA) or, if they already own its stock, sell it.




(adsbygoogle = window.adsbygoogle || []).push({});
